Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives

IF 4.8 2区医学 Q2 IMMUNOLOGY International immunopharmacology Pub Date : 2024-09-05 DOI:10.1016/j.intimp.2024.112949

引用次数: 0

Abstract

MDSCs (myeloid-derived suppressor cells) are crucial for immune system evasion in cancer. They accumulate in peripheral blood and tumor microenvironment, suppressing immune cells like T-cells, natural killer cells and dendritic cells. They promote tumor angiogenesis and metastasis by secreting cytokines and growth factors and contribute to a tumor-promoting environment. The accumulation of MDSCs in cancer patients has been linked to poor prognosis and resistance to various cancer therapies. Targeting MDSCs and their immunosuppressive mechanisms may improve treatment outcomes and enhance immune surveillance by developing drugs that inhibit MDSC function, by preventing their accumulation and by disrupting the tumor-promoting environment. This review presents a detailed overview of the MDSC research in cancer with regulation of their development and function. The relevance of MDSC as a prognostic and predictive biomarker in different types of cancers, along with recent advancements on the therapeutic approaches to target MDSCs are discussed in detail.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

癌症中的髓源性抑制细胞：当前知识与未来展望。

MDSCs（髓源抑制细胞）对免疫系统逃避癌症至关重要。它们积聚在外周血和肿瘤微环境中，抑制 T 细胞、自然杀伤细胞和树突状细胞等免疫细胞。它们通过分泌细胞因子和生长因子，促进肿瘤血管生成和转移，并形成一个有利于肿瘤生长的环境。癌症患者体内 MDSCs 的积累与预后不良和对各种癌症疗法的耐药性有关。以 MDSCs 及其免疫抑制机制为靶点，通过开发抑制 MDSC 功能的药物，防止 MDSCs 聚集并破坏肿瘤促进环境，可改善治疗效果并增强免疫监视。本综述详细概述了癌症中的 MDSC 研究及其发展和功能调控。文中详细讨论了 MDSC 作为不同类型癌症的预后和预测生物标志物的相关性，以及针对 MDSCs 的治疗方法的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International immunopharmacology 医学-免疫学

CiteScore

8.40

自引率

3.60%

发文量

935

审稿时长

53 days

期刊介绍： International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.